Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes

Clinical Biochemistry

Volumn 43, Issue 10-11, 2010, Pages 815-821

  Narasimhan, Sandhya ^a,b,c,d   Gokulakrishnan, Kuppan ^a,b,c,d   Sampathkumar, Rangasamy ^a,b,c,d   Farooq, Syed ^a,b,c,d   Ravikumar, Radhakrishnan ^a,b,c,d   Mohan, Viswanathan ^a,b,c,d   Balasubramanyam, Muthuswamy ^a,b,c,d  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

^b Dr Mohan's Diabetes Specialities Centre   (India)

^c WHO Collaborating Centre for Non Communicable Diseases Prevention and Control   (Canada)

^d IDF Centre of Education   (Belgium)

Author keywords

Asian Indians; Glutathione; NAFLD; Oxidative stress; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; CARBONYL DERIVATIVE; GLUCOSE; GLUTATHIONE; INSULIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; INDIAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PRIORITY JOURNAL; UPREGULATION; BLOOD; COMPLICATION; FATTY LIVER; MIDDLE AGED; PROTEIN CARBONYLATION;

ADULT; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; FATTY LIVER; GLUTATHIONE; HUMANS; INSULIN; INSULIN RESISTANCE; MIDDLE AGED; OXIDATIVE STRESS; PROTEIN CARBONYLATION; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 77953714513     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.04.003     Document Type: Article

References (48)

1. Angulo P. NAFLD, obesity and bariatric surgery. Gastroenterology 2006, 130:1848-1852.
2. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107:1805-1815.
3. Mohan V., Farooq S., Deepa M., Ravikumar R., Pitcumoni C.S. Prevalence of non-alcoholic fatty liver disease in urban South Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 2009, 84:84-91.
4. Malhi H., Gores G.J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28:360-369.
5. Browning D.J., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004, 114:147-152.
6. 2 generation in liver mitochondria. Carcinogenesis 2000, 21:983-989.
7. Bergamini C.M., Gambetti S., Dondi A., Cervellati C. Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 2004, 10:1611-1626.
8. Sanyal A.J., Campbell S.C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
9. Chalasani N., Deeg M.A., Crab D.W. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2004, 99:1497-1502.
10. Yesilova Z., Yaman H., Oktenli C., Ozcan A., Uygun A., Cakir E., et al. Systemic markers of lipid peroxidation and antioxidants in patients with non-alcoholicfatty liver disease. Am J Gastroenterol 2005, 100:850-855.
11. Mohan V., Sharp P.S., Cloke H.R., Burrin J.M., Schumer B., Kohner E.M. Serum immunoreactive insulin responses to a glucose load in Asian Indian and European type 2 (non-insulin-dependent) diabetic patients and control subjects. Diabetologia 1986, 29:235-237.
12. Prashanth M., Ganesh H.K., Vima M.V., John M., Bandgar T., Joshi S.R., et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India 2009, 57:205-210.
13. Deepa M., Pradeepa R., Rema M., Mohan A., Deepa R., Shanthirani S., et al. The Chennai Urban Rural Epidemiology Study (CURES)-study design and methodology (urban component) (CURES-1). J Assoc Physicians India 2003, 51:863-870.
14. Alberti K.G., Zimmet P.Z. Definition diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
15. Joseph A.E., Saverymuttu S.H., Al-sam S., Cook M.G., Maxwell J.D. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991, 43:26-31.
16. Lonardo A., Bellimni M., Tartoni P., Tondelli E. The bright liver syndrome. Prevalence and determinants of a bright liver ECHO pattern. Ital J Gastroenterol Hepatol 1997, 29:351-356.
17. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976, 15:212-216.
18. Levin R.L., Garlan D., Oliver C.N., Amici A., Clement I., Lenz A.G. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990, 186:464-478.
19. Sampath Kumar R., Balasubramanyam M., Tara C., Rema M., Mohan V. Association of hypoglutathionemia with reduced Na+/K+ activity in type 2 diabetes and microangiopathy. Mol Cell Biochem 2006, 282:169-176.
20. Seki S., Kitada T., Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol Res. 2005, 33:132-134.
21. Madan K., Bhardwaj P., Thareja S., Gupta S.D., Saraya A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J Clin Gastroenterol 2006, 40:930-935.
22. Das K.S., Balakrishnan V., Mukherjee S., Vasudevan D.M. Evaluation of blood oxidative stress-related parameters in alcoholic liver disease and non-alcoholic fatty liver disease. Scand J Clin Lab Invest 2008, 68:323-334.
23. Adaikalakoteswari A., Balasubramanyam M., Rema M., Mohan V. Differential gene expression of NADPH oxidase (p22) and hemoxygenase-1 in patients with type 2 diabetes and microangiopathy. Diabet Med 2006, 23:666-674.
24. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132:112-117.
25. Seki S., Kitada T., Yamada T., Sakaguchi H., Nakatani K., Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002, 37:56-62.
26. Adaikalakoteswari A., Balasubramanyam M., Mohan V. Telomere shortening occurs in Asian Indian type 2 diabetic patients. Diabet Med 2005, 22:1151-1156.
27. Videla L.A., Rodrigo R., Araya J., Poniachik J. Oxidative stress and depletion of hepatic polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 2007, 37:1499-1507.
28. Lieber C.S., Leo M.A., Mak K.M., Xu Y., Cao Q., Ren C., et al. Model of nonalcoholic steatohepatitis. Am J Clin Nutr 2004, 79:502-509.
29. Hori M., Oniki K., Nakagawa T., Takata K., Mihara S., Marubayashi T., et al. Association between combinations of glutathione-S-transferase M1, T1 and P1 genotypes and non-alcoholic fatty liver disease. Liver Int 2009, 29:164-168.
30. Piemonte F., Petrini S., Gaeta L.M., Tozzi G., Bertini E., Devito R., et al. Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2008, 23:457-464.
31. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
32. Bugianesi E., Gastaldelli A., Vanni E., Gambino R., Cassader M., Baldi S., Ponti V., Pagano G., Ferrannini E., Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005, 48:634-642.
33. Houstis N., Rosen E.D., Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440:944-948.
34. Cotrim H.P., Carvalho F., Siqueira A.C., Lordelo M., Rocha R., De Freitas L.A. Nonalcoholic fatty liver and insulin resistance among petrochemical workers. JAMA 2005, 294:1618-1620.
35. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
36. Hoehn K.L., Salmon A.B., Hohnen-Behrens C., Turner N., Hoy A.J., Maghzal G.J., et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci USA 2009, 106:17787-17792.
37. Musso G., Gambino R., De Michieli F., Biroli G., Premoli A., Pagano G., et al. Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. Am J Clin Nutr 2007, 86:661-671.
38. Aronis A., Madar Z., Tirosh O. Mechanism underlying oxidative stress mediated lipotoxicity: exposure of J774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis. Free Radic Biol Med 2005, 38:1221-1230.
39. Evans J.L., Maddux B.A., Goldfine I.D. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 2005, 7:1040-1052.
40. Videla L.A., Rodrigo R., Araya J., Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 2006, 12:555-558.
41. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123:745-750.
42. Ekstedt M., Franzén L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
43. Rodríguez-Hernández H., Gonzalez J.L., Márquez-Ramirez M.D., Flores-Hernandez M., Rodríguez-Morán M., Guerrero-Romero F. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes. Eur J Gastroenterol Hepatol 2008, 20:399-403.
44. Adams L.A., Waters O.R., Knuiman M.W., Elliott R.R., Olynyk J.K. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009, 104:861-867.
45. Adams L.A., Angulo P., Lindor K.D. Nonalcoholic fatty liver disease. CMAJ 2005, 172:899-905.
46. Uslusoy H.S., Nak S.G., Gülten M., Biyikli Z. Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol 2009, 15:1863-1868.
47. Ali R., Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 2009, 41:265-278.
48. Diamanti-Kandarakis E., Kouli C., Alexandraki K., Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89:1273-1276.